■ A team of international researchers set out to determine the efficacy and safety of the Xen gel stent (Allergan) in both standalone and combination ab-interno procedures after 3 years. Mean IOP and medications in 163 eyes decreased from 20.7 mmHg and 2.5 medications at baseline to 13.9 mmHg and 1.1 medications at 3 years. Mean changes from baseline in IOP (-5.6, -6.2, and -6.6 mmHg) and medications (-1.8, -1.6, and -1.4) were statistically significant at 1, 2, and 3 years after implantation, respectively. Results appeared comparable when implantation was performed with (n=76) or without (n=98) phacoemulsification. Fifteen eyes had intraoperative complications, 31 experienced 46 postoperative adverse events of special interest, and 26 required secondary surgical interventions. The study was reported in Acta Ophthalmologica.
Article
Xen Stent Effective and Safe at 3 Years
Glaucoma Physician
September 1, 2021
Vol Ophthalmology Management 25, Issue September 2021
Page(s): 6